Lercanidipine-13C,d3-1 (hydrochloride)

Lercanidipine-13C,d3-1 (hydrochloride)

• CAS Number: 2747918-20-1
• UNSPSC Description: Lercanidipine-13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[1][2][3].
• Target Antigen: Calcium Channel; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling;Others
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=C(C)NC(C)=C(C(O[13C]([2H])([2H])[2H])=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C.Cl
• Molecular Weight: 652.20
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70.|[3]Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7.|[4]Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 2017;8(4):155-165.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported